The prolonged use of proton pump inhibitors, drugs used to reduce gastric acidity, has been linked to the development of stomach cancer.
- Proton pump inhibitors like omeprazole, lansoprazole and pantoprazole reduce the acidity of the stomach and promote the healing of stomach ulcers
- Their long-term use has been associated with an increased risk of stomach cancer
- Further studies are required that are designed to specifically address the possible risk
Physicians sometimes advise the long-term use of proton pump inhibitors to reduce gastric acidity after the treatment for H. pylori infection. Scientists gathered data from patients who received treatment for H. pylori infection and were then prescribed either proton pump inhibitors or alternative acid-reducing drugs called H2 blockers over prolonged durations. H2 blockers include drugs like ranitidine, famotidine and nizatidine. The study population included 63,397 adults who were followed up for an average period of 7.5 years. The scientists found that:
Most patients took H2 blockers, while 5% took proton pump inhibitors for an average of around 3 years.
The risk of stomach cancer was more than double in the group taking proton pump inhibitors, while the increased risk was not noted in those taking H2 blockers
The risk increased with:
- A longer duration of use of proton pump inhibitors. The intake of the proton pump inhibitors for more than a year increased the risk 5 times, while an intake for three or more years increased the risk by more than 8 times
- More frequent use of proton pump inhibitors. The risk with the daily use of the proton pump inhibitors was around four times as compared to weekly use.
- Cheung KS, Chan EW, Wong AYS, et al Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study Gut. doi: http://dx.doi.org/10.1136/gutjnl-2017-314605